00000nam 22000008i 4500 9.915979 CaOODSP 20221123103203 m o d f cr cn||||||||| 221006e20220901onc ob f000 0 eng d 9780660457246 (report) 9780660457253 (summary) CaOODSP eng rda CaOODSP n-cn--- HP5-142/1-2022E-1-PDF HP5-142/2-2022E-1-PDF Recommendations on the use of bivalent Omicron-containing mRNA COVID-19 vaccines. Ottawa, ON : Public Health Agency of Canada = Agence de la santé publique du Canada, September 1, 2022. ©2022 1 online resource (27 pages) + 1 summary (8 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier Issued also in French under title: Recommandations sur l'utilisation des vaccins à ARNm bivalents contre la COVID-19 contenant le variant Omicron. At head of title: An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI). "Updated: October 7, 2022." Includes bibliographical references (pages 17-22). "On June 29, 2022, NACI published interim guidance on planning considerations for a fall 2022 COVID-19 vaccine booster program in Canada. The statement outlined recommendations for booster doses in specific populations ahead of the uncertain trajectory of the COVID-19 pandemic in the coming months"--Background, page 3. COVID-19 (Disease) Vaccination Canada. COVID-19 vaccines Canada. Public Health Agency of Canada, issuing body. Recommandations sur l'utilisation des vaccins à ARNm bivalents contre la COVID-19 contenant le variant Omicron. (CaOODSP)9.915980 Recommendations on the use of bivalent Omicron-containing mRNA COVID-19 vaccines. (CaOODSP)9.914912 PDF 1.41 MB https://publications.gc.ca/collections/collection_2022/aspc-phac/HP5-142-1-2022-1-eng.pdf (report) PDF 1.23 MB https://publications.gc.ca/collections/collection_2022/aspc-phac/HP5-142-2-2022-1-eng.pdf (summary)